Using Alzheimer's disease blood tests to accelerate clinical trial enrollment-Reference-Cited by-同舟云学术

Using Alzheimer's disease blood tests to accelerate clinical trial enrollment

Published:2022-08-07 Issue:4 Volume:19 Page:1175-1183
ISSN:1552-5260
Container-title:Alzheimer's & Dementia
language:en
Short-container-title:Alzheimer's & Dementia

Author:

Schindler Suzanne E.¹²^ORCID,Li Yan¹²,Li Melody¹,Despotis Alyssa³,Park Ethan¹,Vittert Liberty³,Hamilton Barton H.³,Womack Kyle B.¹²,Saef Benjamin¹,Holtzman David M.¹²⁴,Morris John C.¹²,Bateman Randall J.¹²⁴,Gupta Mahendra R.³

Affiliation:

1. Department of Neurology Washington University School of Medicine St. Louis Missouri USA

2. Knight Alzheimer Disease Research Center St. Louis Missouri USA

3. Olin Business School Washington University St. Louis Missouri USA

4. Hope Center for Neurological Disorders Washington University School of Medicine St. Louis Missouri USA

Funder

National Institutes of Health

Publisher

Wiley

Subject

Psychiatry and Mental health,Cellular and Molecular Neuroscience,Geriatrics and Gerontology,Neurology (clinical),Developmental Neuroscience,Health Policy,Epidemiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/alz.12754

Reference44 articles.

1. Defeating Alzheimer's disease and other dementias: a priority for European science and society

2. Projecting the long‐term societal value of a disease‐modifying treatment for Alzheimer's disease in the United States

3. Tip of the Iceberg: Assessing the Global Socioeconomic Costs of Alzheimer’s Disease and Related Dementias and Strategic Implications for Stakeholders

4. Appropriate use criteria for amyloid PET: A report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association

5. Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer's disease

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. P-tau217 as a Reliable Blood-Based Marker of Alzheimer’s Disease;Biomedicines;2024-08-13

2. PrecivityAD2™ Blood Test: Analytical Validation of an LC-MS/MS Assay for Quantifying Plasma Phospho-tau217 and Non-Phospho-tau217 Peptide Concentrations That Are Used with Plasma Amyloid-β42/40 in a Multianalyte Assay with Algorithmic Analysis for Detecting Brain Amyloid Pathology;Diagnostics;2024-08-10

3. FDCNN-AS: Federated deep convolutional neural network Alzheimer detection schemes for different age groups;Information Sciences;2024-08

4. Implications of treatment duration and frequency for value and cost-effective price of Alzheimer treatments;Journal of Managed Care & Specialty Pharmacy;2024-07-22

5. Correlations between plasma markers and brain Aβ deposition across the AD continuum: Evidence from SILCODE;Alzheimer's & Dementia;2024-07-10